About US
Contact us
-
FDA says Mylan's Wellbutrin generic stacks up to branded drugMylan ($MYL) is the first drugmaker to make it through FDA scrutiny of its generic of antidepressantWellbutrin XLin a regulatory episode that has reignited debate over the quality ofgenericsversus bra2013/8/26
-
Indian authorities confirm closer look at Ranbaxy operationsQuestions continue to brew in home country months after drugmaker settled with U.S. authorities In the U.S., the furor overRanbaxy Laboratories' misdeeds has largely settled down, but the generics dr2013/8/26
-
Whistleblower: Lilly spent $4.9M bribing Chinese docs to prescribe diabetes medsAnother Chinesewhistleblowerhas targeted Big Pharma. This time, the bribery allegations involve Eli Lilly ($LLY), and 30 million yuan in purported kickbacks to Chinese doctors. That's about $4.9 milli2013/8/23
-
CFDA Minister Zhang Yong meets Czech Health MinisterOn the afternoon of August 20, 2013, Zhang Yong, Minister of China Food and Drug Administration (CFDA), met with the delegation led by Mr. Martin Holcát, Minister of Health of the Czech Republic2013/8/23
-
CFDA Vice Minister Yin Li meets Swiss Federal Councillor and the Ambassador of Switzerland to ChinaOn the morning of August 16, 2013, Yin Li, Vice Minister of China Food and Drug Administration (CFDA) met with the delegation led by Mr. Alain Berset, Swiss Federal Councillor and Head of the Swiss Fe2013/8/22
-
Bayer's Stivarga nabs new approval in newly popular JapanBayer's cancer drugStivargahas racked up another approval. Japanese regulators cleared thecolon cancertreatment for a new use, against gastrointestinal stromal tumors. It's just the latest victory for2013/8/21
-
Alexion pulls Soliris vials on particle-contamination worriesAlexion ($ALXN) had to recall more vials of its rare-disease treatmentSolirisbecause particles were found in some of them. The move comes as Roche ($RHHBY) is reportedly eyeing a bid for the U.S.-base2013/8/21
-
Analyst to Merck: Get to work chopping costs, preferably $1B-plusWhen Merck cut its sales guidance last month, market-watchers predicted cost cuts. Soon, executives would be sharpening their scalpels--or heavier instruments--to compensate. After all, generic compet2013/8/20
-
CFDA Minister Zhang Yong meets Secretary for Food and Health of the Hong Kong SAR GovernmentOn the afternoon of August 12, 2013, Zhang Yong, Minister of China Food and Drug Administration (CFDA), met with the delegation led by Dr. Ko Wing-man, Secretary for Food and Health of the Hong Kong S2013/8/20
-
NICE denies Pfizer lung cancer drug in final guidanceIn the past, the U.K.'s cost-effectiveness gatekeeper has shown that it will bend preliminary draft guidance decisions if the price is right. But for Pfizer ($PFE), which slashed costs on its targeted2013/8/19